Loading..

Inovio Pharmaceuticals, Inc. (INO) Report Analysis

Corporate Events

Positive

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) adde...

2022-06-24 00:00:00

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) added to Russell Microcap Value Index

Positive

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) adde...

2022-06-24 00:00:00

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) added to Russell 3000E Value Index

Positive

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) adde...

2022-06-24 00:00:00

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) added to Russell 3000E Index

Positive

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) adde...

2022-06-24 00:00:00

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) added to Russell Microcap Index

Positive

INOVIO Announces Survival Results for INO-5401 ...

2022-05-27 12:06:00

INOVIO announced results from the company's novel Phase 1/2 trial of INO-5401 and INO-9012 in combination with PD-1 inhibitor Libtayo(R) (cemi...

Neutral

Inovio Pharmaceuticals, Inc. Presents at 2022 J...

2022-05-23 12:00:00

Inovio Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 01:00 PM. Venue: Marriott Marquis, New York ...

Neutral

Inovio Pharmaceuticals, Inc. Presents at The 20...

2022-05-10 23:07:00

Inovio Pharmaceuticals, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 . Venue: McCormick Place, Chicago, Illinois, United States.

Negative

INOVIO Announces Board Changes

2022-05-10 20:05:00

INOVIO announced the appointment of Jacqueline Shea, Ph.D., as President of INOVIO, effective immediately. Dr. Shea succeeds Dr. J. Joseph Kim...

Negative

INOVIO Announces Executive Changes

2022-05-10 20:05:00

INOVIO announced the appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer (CEO) of INOVIO, effective immediately. Dr. Shea succee...

Neutral

Inovio Pharmaceuticals, Inc., Q1 2022 Earnings ...

2022-04-26 12:00:00

Inovio Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 10, 2022

Neutral

Inovio Pharmaceuticals, Inc. to Report Q1, 2022...

2022-04-26 12:00:00

Inovio Pharmaceuticals, Inc. announced that they will report Q1, 2022 results After-Market on May 10, 2022

Neutral

Inovio Pharmaceuticals, Inc. Presents at World ...

2022-04-16 13:52:00

Inovio Pharmaceuticals, Inc. Presents at World Vaccine Congress 2022, Apr-21-2022 09:40 AM. Venue: Marriott Marquis Washington, Washington , D...

Neutral

Inovio Pharmaceuticals, Inc. - Shareholder/Analyst Call

2022-03-25 20:28:00

Annual Meeting of Stockholders

Neutral

Inovio Pharmaceuticals, Inc., Annual General Me...

2022-03-25 20:28:00

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 16, 2022, at 09:00 US Eastern Standard Time. Agenda: To consider to elect eight dire...

Neutral

Inovio Pharmaceuticals, Inc. Presents at Bank o...

2022-03-23 02:30:00

Inovio Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-2022 10:00 AM. Venue: Encore Hotel, 3121 Las Vegas...

Neutral

Bank of America Corporation, Bank of America 20...

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vega...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

Terrapinn Holdings Ltd, World Vaccine Congress ...

2022-01-27 09:13:00

Terrapinn Holdings Ltd, World Vaccine Congress 2022, Apr 18, 2022 through Apr 22, 2022. Venue: Marriott Marquis Washington, Washington , Distr...

Positive

INOVIO Updates on Phase 3 Program for VGX-3100 ...

2021-12-14 13:00:00

INOVIO announced updates on the Phase 3 program for VGX-3100 for HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL), i...

Neutral

American Society Of Clinical Oncology, Inc., th...

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago,...

Neutral

Inovio Pharmaceuticals, Inc. Presents at Piper ...

2021-11-22 15:06:00

Inovio Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-30-2021 08:00 AM. Venue: New York, New Y...

Positive

INOVIO Collaborates with GuardRX and Geneva Uni...

2021-11-16 13:00:00

INOVIO announced that several volunteers have been dosed with its DNA-based, intradermal Ebola vaccine candidate, INO-4201, as part of a rando...

Positive

Inovio Receives U.S. FDA Authorization to Proce...

2021-11-09 13:00:00

Inovio Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) provided authorization to proceed for INOVIO's INNOVAT...

Negative

Inovio Pharmaceuticals, Inc. has filed a Follow...

2021-11-09 00:00:00

Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million. Security Name: Common Stock Security Typ...

Negative

Inovio Pharmaceuticals, Inc. Expands Executive ...

2021-11-05 12:00:00

INOVIO announced the strategic appointments of new leaders designed to position INOVIO for growth and upcoming commercial operations. Effectiv...

Positive

INOVIO Further Expands Innovate Phase 3 Trial f...

2021-11-03 12:00:00

INOVIO announced that it has received authorization from India'sCentral Drugs Standard Control Organization (CDSCO)'s Drug Controller General ...

Neutral

Medimmune Limited Provides Notice to Inovio Pha...

2021-10-29 21:01:00

On October 28, 2021, MedImmune Limited (MedImmune") provided notice to Inovio Pharmaceuticals, Inc. (the Company") to terminate the INO-3112 /...

Neutral

Inovio Pharmaceuticals, Inc., Q3 2021 Earnings ...

2021-10-27 12:00:00

Inovio Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 09, 2021

Neutral

Inovio Pharmaceuticals, Inc. to Report Q3, 2021...

2021-10-27 12:00:00

Inovio Pharmaceuticals, Inc. announced that they will report Q3, 2021 results After-Market on Nov 09, 2021

Positive

INOVIO Completes Enrollment of Phase 1B Clinica...

2021-10-26 12:00:00

INOVIO announced its Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, completed full enrollment of 220 partici...

Neutral

INOVIO Announces Collaboration with Colombia; M...

2021-10-21 12:00:00

INOVIO announced the signing of a non-binding memorandum of understanding (MOU) with Colombia's Ministry of Health and Social Protection refle...

Positive

Inovio Pharmaceuticals, Inc. Announces Online P...

2021-10-12 12:00:00

Inovio Pharmaceuticals, Inc. announced the online preprint publication in MedRxiv of Phase 1 clinical data on homologous boosting of its COVID...

Positive

INOVIO Expands Phase 3 for INO-4800, its DNA Va...

2021-10-11 12:00:00

Inovio Pharmaceuticals, Inc. announced that it has received authorization from Colombia'sINVIMA (Instituto Nacional de Vigilancia de Medicamen...

Neutral

Inovio Pharmaceuticals, Inc. Presents at World ...

2021-09-24 19:02:00

Inovio Pharmaceuticals, Inc. Presents at World Antiviral Congress 2021, Nov-30-2021 02:25 PM. Venue: San Diego, California, United States. Spe...

Neutral

Terrapinn Inc, World Antiviral Congress 2021, N...

2021-09-23 19:35:00

Terrapinn Inc, World Antiviral Congress 2021, Nov 30, 2021 through Dec 02, 2021. Venue: San Diego, California, United States.

Neutral

Inovio Pharmaceuticals, Inc. Presents at Festiv...

2021-09-22 15:38:00

Inovio Pharmaceuticals, Inc. Presents at Festival of Biologics Basel 2021, Nov-10-2021 12:10 PM. Venue: Congress Centre, Basel, Switzerland. S...

Positive

INOVIO Receives Regulatory Authorization to Con...

2021-09-22 12:00:00

INOVIO announced that it has received authorization from COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), the nationa...

Neutral

Inovio Pharmaceuticals, Inc. Presents at Oppenh...

2021-09-02 03:36:00

Inovio Pharmaceuticals, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-21-2021 09:55 AM. Speakers: J. Josep...

Neutral

Inovio Pharmaceuticals, Inc. Presents at H.C. W...

2021-09-02 03:36:00

Inovio Pharmaceuticals, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York...

Neutral

Inovio Pharmaceuticals, Inc. Presents at Cantor...

2021-09-02 03:36:00

Inovio Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 10:00 AM. Venue: New York, United States. Speak...

Positive

INOVIO Receives Authorization to Conduct Phase ...

2021-08-26 12:00:00

INOVIO announced that it has received regulatory authorization from Brazil'sANVISA (Agência Nacional de Vigilância Sanitária), the national he...

Neutral

Inovio Pharmaceuticals, Inc. Presents at World ...

2021-08-18 15:33:00

Inovio Pharmaceuticals, Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 02:25 PM. Venue: Loews Coronado B...

Neutral

Inovio Pharmaceuticals, Inc. Presents at Next G...

2021-08-16 06:25:00

Inovio Pharmaceuticals, Inc. Presents at Next Generation Cancer Vaccine Development Summit, Sep-08-2021 02:15 PM. Speakers: Laurent M. Humeau,...

Positive

INOVIO and Advaccine Receive Regulatory Allowan...

2021-08-09 12:00:00

INOVIO announced that it has received regulatory allowance for two clinical trials investigating heterologous boosting with INO-4800, its DNA ...

Positive

INOVIO Doses First Participant in Phase 2 Trial...

2021-08-04 12:00:00

INOVIO announced that the company has dosed the first Phase 2 trial subject in its quest to develop the first vaccine against the Middle East ...

Neutral

Inovio Pharmaceuticals, Inc., Q2 2021 Earnings ...

2021-07-26 12:00:00

Inovio Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 09, 2021

Neutral

Inovio Pharmaceuticals, Inc. to Report Q2, 2021...

2021-07-26 12:00:00

Inovio Pharmaceuticals, Inc. announced that they will report Q2, 2021 results After-Market on Aug 09, 2021

Neutral

Terrapinn Holdings Ltd, World Vaccine & Immunot...

2021-07-22 01:45:00

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021. Venue: Loews Coronado Bay R...

Neutral

Oppenheimer & Co. Inc., Oppenheimer Fall Health...

2021-07-21 14:31:00

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.

Neutral

Inovio Pharmaceuticals, Inc. Presents at Diseas...

2021-07-19 13:07:00

Inovio Pharmaceuticals, Inc. Presents at Disease Prevention and Control Summit America 2021, Jul-20-2021 01:50 PM. Venue: New York, New York, ...

Neutral

Terrapinn Holdings Ltd, NRx Pharmaceuticals, In...

2021-07-19 10:48:00

Terrapinn Holdings Ltd, NRx Pharmaceuticals, Inc., Disease Prevention and Control Summit America 2021, Jul 20, 2021 through Jul 21, 2021. Venu...

Positive

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) added to Russell Microcap Value Index

2022-06-24 00:00:00

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) added to Russell Microcap Value Index

Positive

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) added to Russell 3000E Value Index

2022-06-24 00:00:00

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) added to Russell 3000E Value Index

Positive

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) added to Russell 3000E Index

2022-06-24 00:00:00

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) added to Russell 3000E Index

Positive

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) added to Russell Microcap Index

2022-06-24 00:00:00

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) added to Russell Microcap Index

Positive

INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo(R) (cemiplimab) in Patients with Newly Diagnosed GBM

2022-05-27 12:06:00

INOVIO announced results from the company's novel Phase 1/2 trial of INO-5401 and INO-9012 in combination with PD-1 inhibitor Libtayo(R) (cemiplimab) in the treatment of newly diagnosed glioblastoma (GBM), including encouraging median overall survival (OS) data from fifty-two subjects. Median OS duration in unmethylated MGMT (Cohort A) was 17.9 months. Median OS data in MGMT Methylated patients (Cohort B) are being presented for the first time, at a median of 32.5 months, which compares favorably to historical comparisons (23.2-25 months). Overall, INO-5401 + INO-9012 is demonstrated to be tolerable and immunogenic when administered with Libtayo and RT/TMZ (radiation and temozolomide) to newly diagnosed GBM patients. Notably, INO-5401 elicited antigen-specific T cells that may infiltrate GBM tumors. The data from this study was selected to be presented in an oral presentation by Dr. David Reardon on, June 6, 2022, at the 2022 American Society of Clinical Oncology (ASCO) at the McCormick Place Convention Center in Chicago, Illinois. The adverse event profile was consistent with known single-agent (INO-5401, INO-9012, EP or Libtayo) events; most events were <=Grade 2 and no related events were Grade >=4. Median OS durations in Cohorts A and B were 17.9 months (95% CI 14.5-19.8) and 32.5 months (95% CI 18.4-not reached), respectively. Flow cytometry revealed activated, antigen specific CD4+CD69+PD1+ and CD8+CD69+PD1+ T cells, the latter with lytic potential as defined by presence of perforin and granzymeA. Both subsets exhibited HR < 1.0 and p < 0.05 when accounting for a 0.1% T cell frequency change, translating to a 23% and 28% reduced risk of death at 18 months, respectively.

Neutral

Inovio Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 01:00 PM

2022-05-23 12:00:00

Inovio Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 01:00 PM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Jacqueline E. Shea, CEO, President & Director, Jeffrey Skolnik, Senior Vice President of Clinical Development.

Neutral

Inovio Pharmaceuticals, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022

2022-05-10 23:07:00

Inovio Pharmaceuticals, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 . Venue: McCormick Place, Chicago, Illinois, United States.

Negative

INOVIO Announces Board Changes

2022-05-10 20:05:00

INOVIO announced the appointment of Jacqueline Shea, Ph.D., as President of INOVIO, effective immediately. Dr. Shea succeeds Dr. J. Joseph Kim in these roles. Dr. Kim has also resigned as a member of the INOVIO board of directors, and the board intends to appoint Dr. Shea as a director following INOVIO's annual meeting of the stockholders on May 16, 2022. Prior to joining INOVIO in March 2019, Dr. Shea served as the Chief Operating Officer and later the Chief Executive Officer of Aeras.

Negative

INOVIO Announces Executive Changes

2022-05-10 20:05:00

INOVIO announced the appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer (CEO) of INOVIO, effective immediately. Dr. Shea succeeds Dr. J. Joseph Kim in these roles. Prior to joining INOVIO in March 2019, Dr. Shea served as the Chief Operating Officer and later the Chief Executive Officer of Aeras.

Neutral

Inovio Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 10, 2022

2022-04-26 12:00:00

Inovio Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 10, 2022

Neutral

Inovio Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022

2022-04-26 12:00:00

Inovio Pharmaceuticals, Inc. announced that they will report Q1, 2022 results After-Market on May 10, 2022

Neutral

Inovio Pharmaceuticals, Inc. Presents at World Vaccine Congress 2022, Apr-21-2022 09:40 AM

2022-04-16 13:52:00

Inovio Pharmaceuticals, Inc. Presents at World Vaccine Congress 2022, Apr-21-2022 09:40 AM. Venue: Marriott Marquis Washington, Washington , District Of Columbia, United States. Speakers: Joseph Kim, CEO.

Neutral

Inovio Pharmaceuticals, Inc. - Shareholder/Analyst Call

2022-03-25 20:28:00

Annual Meeting of Stockholders

Neutral

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 16, 2022

2022-03-25 20:28:00

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 16, 2022, at 09:00 US Eastern Standard Time. Agenda: To consider to elect eight directors to hold office until 2023 annual meeting of stockholders and until their successors are elected and duly qualified; to ratify the appointment by the audit committee of the board of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2022; to approve, on a non-binding advisory basis, the compensation of named executive officers we describe in accompanying proxy statement; and to transact such other business as may properly come before the meeting.

Neutral

Inovio Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-2022 10:00 AM

2022-03-23 02:30:00

Inovio Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-2022 10:00 AM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: J. Joseph Kim, CEO, President & Director.

Neutral

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Terrapinn Holdings Ltd, World Vaccine Congress 2022, Apr 18, 2022 through Apr 22, 2022

2022-01-27 09:13:00

Terrapinn Holdings Ltd, World Vaccine Congress 2022, Apr 18, 2022 through Apr 22, 2022. Venue: Marriott Marquis Washington, Washington , District Of Columbia, United States.

Positive

INOVIO Updates on Phase 3 Program for VGX-3100 for HPV-Associated Cervical High-Grade Squamous Intraepithelial Lesions

2021-12-14 13:00:00

INOVIO announced updates on the Phase 3 program for VGX-3100 for HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL), including a one-year follow-up of efficacy and safety data in participants from REVEAL1, completing enrollment in REVEAL2, and advancing its pre-treatment biomarker candidate for VGX-3100 to be further developed with QIAGEN. In addition, INOVIO's development partner within Greater China (mainland China, Hong Kong, Macao, Taiwan), ApolloBio Corp. ("ApolloBio"), dosed the first participant in a separate Phase 3 trial in China. Key Updates for VGX-3100: REVEAL2 – INOVIO's second global Phase 3 clinical trial of VGX-3100 for cervical HSIL is fully enrolled and top-line efficacy and safety data are expected to be available in 2H22. REVEAL1 – the company completed the 52-week safety follow-up of participants in REVEAL1, company's first global Phase 3 trial of VGX-3100, and the safety profile of VGX-3100 observed at Week 36 remained well-tolerated through Week 88. In addition, participants treated with VGX-3100 who met the primary endpoint at Week 36 remained clear of HPV-16 and/or HPV-18 at Week 88. Pre-treatment Biomarker – INOVIO and QIAGEN have made progress in biomarker development by identifying candidate biomarker signatures for VGX-3100 with the intent of selecting a final signature in a pre-treatment in vitro diagnostic to improve the primary clinical outcome for biomarker-positive patients with cervical HSIL. Phase 3 Trial in China – The first participant has been dosed in the Phase 3 trial of VGX-3100 for cervical HSIL in China. This trial is being run by ApolloBio and is similar in design to REVEAL2. The trial is expected to enroll up to 84 participants.

Neutral

American Society Of Clinical Oncology, Inc., the 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago, Illinois, United States.

Neutral

Inovio Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-30-2021 08:00 AM

2021-11-22 15:06:00

Inovio Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-30-2021 08:00 AM. Venue: New York, New York, United States.

Positive

INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201

2021-11-16 13:00:00

INOVIO announced that several volunteers have been dosed with its DNA-based, intradermal Ebola vaccine candidate, INO-4201, as part of a randomized, placebo-controlled, Phase 1b clinical trial (NCT04906629). The trial will assess whether INO-4201 can be used as a booster in healthy volunteers previously vaccinated with rVSV-ZEBOV (Ervebo®1), an FDA- and EMA-approved viral-based vector Ebola vaccine. It follows INOVIO's pre-clinical and Phase 1 trials which suggested to investigators that INO-4201 was well-tolerated and resulted in 100% seroconversion after two doses. Investigators plan to recruit approximately 50 healthy volunteers to participate in the clinical trial. The trial will evaluate the safety, tolerability, and immunogenicity of INO-4201 in healthy adult volunteers who previously received a single intramuscular injection of rVSV-ZEBOV (Ervebo). Ervebo is approved by the U.S. Food and Drug Administration (FDA) for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older as a single dose administration. Ervebo is a replication-competent, live, attenuated recombinant vesicular stomatitis virus (rVSV) -based vaccine. Trial participants will be randomized to either INO-4201 or placebo (4:1 ratio) and will receive an intradermal injection followed by electroporation using INOVIO's CELLECTRA® 2000 smart delivery device. The primary outcome measures include the incidence of adverse events related to INO-4201 from day 0 to 14, and levels of antibodies that bind to Ebola virus surface glycoprotein antigen four weeks after injection.The trial is being coordinated by GuardRX, a non-profit organization whose goal is to spur development of and access to life-saving therapeutics. Its sponsor is the Geneva University Hospitals, which conducted one of the first randomized trials testing the Ervebo vaccine in 2014. The trial is funded by the U.S. Defense Advanced Research Projects Agency (DARPA). The information herein does not necessarily reflect the position or the policy of the U.S. Government, and no official endorsement should be inferred. INO-4201 is composed of a precisely designed DNA plasmid that is injected intradermally followed by electroporation using a proprietary smart device, which delivers the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune response. As one of the only nucleic acid-based vaccine candidates INO-4201 is stable at room temperature for more than a year, at 37°C for more than a month, has a five-year projected shelf life at normal refrigeration temperature and does not need to be frozen during transport or storage.

Positive

Inovio Receives U.S. FDA Authorization to Proceed with Innovate Phase 3 Segment for Its Covid-19 Vaccine Candidate, INO-4800, in the U.S

2021-11-09 13:00:00

Inovio Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) provided authorization to proceed for INOVIO's INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S. The FDA has lifted the partial clinical hold following the FDA's review of additional non-clinical, clinical, and device information provided by INOVIO. INOVIO is partnering with Advaccine Biopharmaceuticals Suzhou Co. Ltd. to conduct the INNOVATE Phase 3 segment in multiple countries in the Americas, Asia, and Africa. The global Phase 3 segment of INNOVATE will evaluate the efficacy of INO-4800 in a two-dose regimen (2.0 mg per dose), administered one month apart, in a 2-to-1 randomization in men and non-pregnant women 18 years of age and older. The primary endpoint of this case-driven Phase 3 trial is virologically confirmed symptomatic COVID-19.

Negative

Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

2021-11-09 00:00:00

Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million. Security Name: Common Stock Security Type: Common Stock Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,480,483 Price\Range: $3.52 Discount Per Security: $0.1056 Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,502,269 Price\Range: $3.52 Discount Per Security: $0.1056 Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering

Negative

Inovio Pharmaceuticals, Inc. Expands Executive Leadership to Prepare for Commercial Operations

2021-11-05 12:00:00

INOVIO announced the strategic appointments of new leaders designed to position INOVIO for growth and upcoming commercial operations. Effective immediately, four experienced and talented leaders will all join the executive team and report to INOVIO's President and CEO, Dr. J. Joseph Kim. Mark Twyman is appointed to the newly created Chief Commercial Officer role. Mark joined INOVIO in 2017 to drive the company's global commercialization efforts. Prior to joining INOVIO, Mark held various VP and SVP level commercial roles with Novavax, Sanofi-Genzyme, GI Dynamics, LENSAR, MedImmune, and Merck; as well as senior advisory roles to pharmaceutical and biotech organizations. Rob Crotty joins INOVIO as its new General Counsel. Rob brings more than 15 years' experience in the life sciences industry. Prior to joining INOVIO, Rob held legal positions of increasing responsibilities at ImClone Systems Incorporated, NPS Pharmaceuticals, Dendron Corporation, Vernalis Therapeutics, and most recently, Nabriva Therapeutics where he served as General Counsel & Secretary. Asli Gevgilili is appointed as INOVIO's Chief Human Resources Officer. She will be responsible for the strategy, planning, and implementation of all human resource-related functions. Asli joins INOVIO from Allergan (acquired by AbbVie), where she spent nearly 10 years in HR leadership roles of increasing responsibility; prior to Allergan, she spent eight years at Merck and Schering Plough, where she held HR Business Partner roles supporting different business functions. Gene Kim is appointed to the newly created position of Chief Corporate Affairs Officer and will continue in his role as President of INOVIO Asia. Gene joined INOVIO as the President of INOVIO Asia in 2020. In his new role, Gene will oversee all communications functions for INOVIO, including investor and public relations. Gene brings more than 20 years of experience in finance and corporate strategy.

Positive

INOVIO Further Expands Innovate Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 with Regulatory Authorization from India

2021-11-03 12:00:00

INOVIO announced that it has received authorization from India'sCentral Drugs Standard Control Organization (CDSCO)'s Drug Controller General of India (DCGI) to proceed with the Phase 3 segment of INOVIO's global Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy), in India for INO-4800, its DNA vaccine candidate for COVID-19. INOVIO is partnering with Advaccine Biopharmaceuticals Suzhou Co. Ltd. (Advaccine) to conduct the INNOVATE Phase 3 segment in multiple countries in Latin America, Asia, and Africa. Regulatory authorization in India follows authorizations from health authorities in Brazil, Philippines, Mexico and Colombia. The global Phase 3 segment of INNOVATE will evaluate the efficacy of INO-4800 in a two-dose regimen (2.0 mg per dose), administered one month apart, in a 2-to-1 randomization in men and non-pregnant women 18 years of age and older. The primary endpoint of this case-driven Phase 3 trial is virologically confirmed symptomatic COVID-19. INNOVATE's Phase 3 segment builds upon the Phase 2 segment, which was conducted in the U.S. and funded by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, in coordination with the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency. Interim Phase 2 data from the ongoing study was disclosed in a pre-print in MedRxiv in May 2021 and showed INO-4800 to be well-tolerated and immunogenic in adults 18 and older. In another previously disclosed study using clinical samples, INO-4800 was also found to provide broad cross-reactive immune responses, including neutralizing antibodies and notable T cell responses, against variants of concern (alpha, beta, gamma and, in subsequent research, delta) – factors which could be critical in containing COVID-19 as it shifts from pandemic to endemic spread. This news builds on gINOVIO's previously announced authorization to proceed in China with two Advaccine-sponsored clinical trials investigating the safety, tolerability, and immunogenicity of heterologous boost combinations with INO-4800, as well as recent positive homologous boosting data for INO-4800, which was found to produce robust immune responses and was well-tolerated as both a two-dose series and as a homologous booster dose in all adults, including participants 65 years of age and older. Of note, a durable antibody response was observed six months following the second dose, and a homologous booster dose administered 6 to 10.5 months following the second dose also significantly increased antibody and T cell responses. INO-4800 was well-tolerated, with no treatment-related serious adverse events reported. Most adverse events were mild in severity and did not increase in frequency with age and subsequent dosing.

Neutral

Medimmune Limited Provides Notice to Inovio Pharmaceuticals, Inc. to Terminate the INO-3112 / Medi0457 Development Program Under That Certain DNA Cancer Vaccine Collaboration Agreement

2021-10-29 21:01:00

On October 28, 2021, MedImmune Limited (MedImmune") provided notice to Inovio Pharmaceuticals, Inc. (the Company") to terminate the INO-3112 /MEDI0457 development program under that certain DNA Cancer Vaccine Collaboration Agreement, dated August 7, 2015, by and between the Company and MedImmune (the Collaboration Agreement"). As a result of the termination, the Collaboration Agreement has been terminated in its entirety. Under the Collaboration Agreement, MedImmune acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus types 16 and 18, with the ability to sublicense those license rights. The Collaboration Agreement permitted MedImmune to terminate the agreement at any time on a program-by- program, product-by-product and/or country-by-country basis. Following the termination of the Collaboration Agreement, the Company will reacquire the rights to INO-3112 and will no longer be entitled to receive potential future milestone payments or royalties under the Collaboration Agreement. The Company will also cease any development activities for which it would be entitled to seek reimbursement from MedImmune. The parties will continue to have rights to jointly publish work relating to the product candidate. MedImmune is currently conducting a Phase 2 clinical trial of MEDI0457 in patients with head and neck squamous cell carcinomas (HNSCC). MedImmune has completed the final data cut off for the trial and plans to complete the clinical study report by the end of 2022. The Company expects that MedImmune will continue to sponsor this study until study termination. MedImmune will also continue providing financial support for an externally sponsored research study of MEDI0457 with The University of Texas MD Anderson Cancer Center until study completion. The Company is no longer substantially dependent on the Collaboration Agreement.

Neutral

Inovio Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 09, 2021

2021-10-27 12:00:00

Inovio Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 09, 2021

Neutral

Inovio Pharmaceuticals, Inc. to Report Q3, 2021 Results on Nov 09, 2021

2021-10-27 12:00:00

Inovio Pharmaceuticals, Inc. announced that they will report Q3, 2021 results After-Market on Nov 09, 2021

Positive

INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa

2021-10-26 12:00:00

INOVIO announced its Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, completed full enrollment of 220 participants. This trial (LSV-002 - NCT04093076) is ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, and is the first vaccine clinical trial for Lassa fever conducted in West Africa, where the viral illness is endemic. INOVIO is advancing INO-4500 with full funding from the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership between public, private, philanthropic, and civil society organizations to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people in need during outbreaks.

Neutral

INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives

2021-10-21 12:00:00

INOVIO announced the signing of a non-binding memorandum of understanding (MOU) with Colombia's Ministry of Health and Social Protection reflecting the intent to advance efforts to combat the pandemic and endemic threat posed by COVID-19 and to better prepare for future public health emergencies. The MOU creates a framework for a collaboration arrangement under which INOVIO and the government plan to explore knowledge sharing, technology licensing, and capacity building that support developing and producing vaccines and other biopharmaceuticals in Colombia. The potential results of these efforts include developing local manufacturing capabilities for INOVIO's DNA medicines and related products and technologies. The framework of the planned collaboration builds on INOVIO's recently announced authorization to proceed in Colombia with the Phase 3 segment of its global Phase 2/3 clinical trial, INNOVATE, for INO-4800, the company's DNA vaccine candidate for COVID-19. INOVIO is working with partner Advaccine Biopharmaceuticals Suzhou Co. Ltd. (Advaccine) on the INNOVATE Phase 3 segment in multiple countries, with a focus on countries underserved by COVID-19 vaccines throughout Latin America, Asia, and Africa. INOVIO previously announced approvals to conduct the trial in Brazil, the Philippines, and Mexico.

Positive

Inovio Pharmaceuticals, Inc. Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800

2021-10-12 12:00:00

Inovio Pharmaceuticals, Inc. announced the online preprint publication in MedRxiv of Phase 1 clinical data on homologous boosting of its COVID-19 DNA vaccine candidate, INO-4800. The paper, titled "SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial," found that among the full Phase 1 cohort of 120 participants – of which 82.5%, or 99 participants, received a booster (or third) dose – INO-4800 produced robust immune responses and was well-tolerated as both a two-dose series and as a homologous booster dose in all adults, including participants 65 years of age and older. Of note, a durable antibody response was observed six months following the second dose, and a homologous booster dose administered 6 to 10.5 months following the second dose also significantly increased antibody and T cell responses. INO-4800 was well-tolerated, with no treatment-related serious adverse events reported. Most adverse events were mild in severity and did not increase in frequency with age and subsequent dosing.

Positive

INOVIO Expands Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization

2021-10-11 12:00:00

Inovio Pharmaceuticals, Inc. announced that it has received authorization from Colombia'sINVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos, or the National Food and Drug Surveillance Institute), to conduct the Phase 3 segment of INOVIO's global Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy) in Colombia, for INO-4800, its DNA vaccine candidate for COVID-19. INOVIO is working with partner Advaccine Biopharmaceuticals Suzhou Co. Ltd. (Advaccine) on the INNOVATE Phase 3 segment in multiple countries, with a focus on countries in Latin America, Asia, and Africa. INOVIO recently announced that it has received regulatory authorization to proceed in Brazil, Philippines, and Mexico. The global Phase 3 segment of INNOVATE will evaluate the efficacy of INO-4800 in a two-dose regimen (2.0 mg per dose), administered one month apart, in a 2-to-1 randomization in men and non-pregnant women 18 years of age and older. The primary endpoint of this case-driven Phase 3 trial is virologically confirmed COVID-19.

Neutral

Inovio Pharmaceuticals, Inc. Presents at World Antiviral Congress 2021, Nov-30-2021 02:25 PM

2021-09-24 19:02:00

Inovio Pharmaceuticals, Inc. Presents at World Antiviral Congress 2021, Nov-30-2021 02:25 PM. Venue: San Diego, California, United States. Speakers: Laurent M. Humeau, Chief Scientific Officer.

Neutral

Terrapinn Inc, World Antiviral Congress 2021, Nov 30, 2021 through Dec 02, 2021

2021-09-23 19:35:00

Terrapinn Inc, World Antiviral Congress 2021, Nov 30, 2021 through Dec 02, 2021. Venue: San Diego, California, United States.

Neutral

Inovio Pharmaceuticals, Inc. Presents at Festival of Biologics Basel 2021, Nov-10-2021 12:10 PM

2021-09-22 15:38:00

Inovio Pharmaceuticals, Inc. Presents at Festival of Biologics Basel 2021, Nov-10-2021 12:10 PM. Venue: Congress Centre, Basel, Switzerland. Speakers: Kate E. Broderick, Senior Vice President of Research & Development.

Positive

INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico

2021-09-22 12:00:00

INOVIO announced that it has received authorization from COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), the national health regulatory agency of Mexico, to conduct a clinical trial in that country as part of the Phase 3 segment of INOVIO's global Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy), for its DNA vaccine candidate for COVID-19, INO-4800. INOVIO is working with its partner Advaccine Biopharmaceuticals Suzhou Co. Ltd. (Advaccine) on the INNOVATE Phase 3 segment in multiple countries. INOVIO recently announced that it has received regulatory authorization to proceed with Phase 3 clinical trials in Brazil and the Philippines and is seeking authorization to conduct trials in additional countries. The global Phase 3 segment of INNOVATE will evaluate the efficacy of INO-4800 in a two-dose regimen (2.0 mg per dose), administered one month apart, in a 2-to-1 randomization in men and non-pregnant women 18 years of age and older. The primary endpoint of this case-driven Phase 3 trial is virologically confirmed COVID-19. INNOVATE's Phase 3 segment builds upon the Phase 2 segment, which was conducted in the U.S. and funded by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, in coordination with the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency. Phase 2 data was disclosed in a pre-print in MedRxiv in May 2021 and found INO-4800 to be well-tolerated and immunogenic in adults 18 and older. In another previously disclosed study using clinical samples, INO-4800 was also found to provide broad cross-reactive immune responses, including neutralizing antibodies and robust T cell responses, against variants of concern (alpha, beta, gamma and, in subsequent research, delta) – factors which could be critical in containing COVID-19 as it shifts from pandemic to endemic spread. INOVIO also announced in August the authorization to proceed in China with two Advaccine-sponsored clinical trials investigating the safety, tolerability, and immunogenicity of heterologous boost combinations with INO-4800 and Sinovac Biotechnology's CoronaVac®, an inactivated COVID-19 vaccine developed by Sinovac and authorized for emergency use by the World Health Organization.

Neutral

Inovio Pharmaceuticals, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-21-2021 09:55 AM

2021-09-02 03:36:00

Inovio Pharmaceuticals, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-21-2021 09:55 AM. Speakers: J. Joseph Kim, CEO, President & Director.

Neutral

Inovio Pharmaceuticals, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-09-02 03:36:00

Inovio Pharmaceuticals, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: J. Joseph Kim, CEO, President & Director.

Neutral

Inovio Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 10:00 AM

2021-09-02 03:36:00

Inovio Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 10:00 AM. Venue: New York, United States. Speakers: J. Joseph Kim, CEO, President & Director.

Positive

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its Covid-19 DNA Vaccine Candidate, INO-4800

2021-08-26 12:00:00

INOVIO announced that it has received regulatory authorization from Brazil'sANVISA (Agência Nacional de Vigilância Sanitária), the national health regulatory agency of Brazil, to initiate the global Phase 3 segment of its Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy), for INO-4800, its DNA vaccine candidate for COVID-19. INOVIO plans to conduct the global INNOVATE Phase 3 segment in multiple countries, including Brazil, with partner Advaccine Biopharmaceuticals Suzhou Co. Ltd. (Advaccine). The global Phase 3 segment of the INNOVATE Phase 2/3 clinical trial will evaluate the efficacy of INO-4800 in a two-dose regimen (2.0 mg per dose), administered one month apart, in a two-to-one randomization in men and non-pregnant women 18 years of age and older in several countries across Latin America, Asia, and Africa. The primary endpoint of this case-driven Phase 3 trial is virologically confirmed COVID-19. INOVIO's DNA medicines have shown the following overall characteristics: Well-tolerated and Easy to Administer: INO-4800 has a strong safety profile and, unlike other COVID-19 vaccine candidates, INO-4800 is administered intradermally and has caused only very limited side effects (mostly mild injection site reactions). Immunogenic: INO-4800 demonstrated robust immune responses: 100% of Phase 1 participants demonstrated overall immunological response rates and had balanced neutralizing antibodies and favorable T-cell responses (CD8 and CD4). Stable and Transportable: INO-4800 has a favorable thermostability profile. The vaccine candidate is projected to be stable at room temperature for more than a year, at 37°C for more than a month, has a 3 to 5-year projected shelf life at 2-8°C and does not need to be frozen during transport or storage – a critical element when considering the feasibility of global distribution. Characterizable and Scalable: INO-4800 is highly characterizable, scalable to population levels, and safe. The highly characterizable nature of the vaccine enables timely scaling of manufacturing with multiple manufacturing facilities able to be utilized. Repeat Administration: INO-4800 can be safely readministered offering the potential for seasonal boosting usage without any concerns of generating an anti-vector response or formulation related issues. The global Phase 3 segment of the Phase 2/3 INNOVATE trial builds upon the Phase 2 segment conducted in the U.S., which was funded by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency. Results from the trial can be found in the paper entitled "Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A Preliminary Report of a Randomized, Blinded, Placebo-controlled, Phase 2 Clinical Trial in Adults at High Risk of Viral Exposure," which has been disclosed in a pre-print in MedRxiv prior to peer review. Early INO-4800 research and development funding were provided by the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill & Melinda Gates Foundation. The Phase 2 data showed INO-4800 was well-tolerated and immunogenic in adults 18 and older. In another previously disclosed study using clinical samples, INO-4800 was also found to provide broad cross-reactive immune responses, including neutralizing antibodies and robust T cell responses, against variants of concern (alpha, beta, gamma and – in subsequent research – delta) – factors which could be critical in containing the SARS-CoV-2 virus as it shifts from pandemic to endemic spread. Earlier this month, INOVIO announced the authorization to proceed in China with two clinical trials investigating heterologous boosting with INO-4800 through Advaccine as the trial sponsor. Working with Sinovac Biotechnology (Sinovac), Advaccine will evaluate the safety, tolerability, and immunogenicity of heterologous prime-boost sequential immunizations using INO-4800 and CoronaVac®, an inactivated COVID-19 vaccine developed by Sinovac and authorized for emergency use by the World Health Organization.

Neutral

Inovio Pharmaceuticals, Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 02:25 PM

2021-08-18 15:33:00

Inovio Pharmaceuticals, Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 02:25 PM. Venue: Loews Coronado Bay Resort, San Diego, California, United States. Speakers: Laurent M. Humeau, Chief Scientific Officer.

Neutral

Inovio Pharmaceuticals, Inc. Presents at Next Generation Cancer Vaccine Development Summit, Sep-08-2021 02:15 PM

2021-08-16 06:25:00

Inovio Pharmaceuticals, Inc. Presents at Next Generation Cancer Vaccine Development Summit, Sep-08-2021 02:15 PM. Speakers: Laurent M. Humeau, Chief Scientific Officer.

Positive

INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate

2021-08-09 12:00:00

INOVIO announced that it has received regulatory allowance for two clinical trials investigating heterologous boosting with INO-4800, its DNA vaccine candidate for COVID-19, through partner and trial-sponsor Advaccine Biopharmaceuticals Suzhou Co. Ltd. ("Advaccine") together with Sinovac Biotechnology ("Sinovac"). The studies will evaluate the safety, tolerability and immunogenicity of heterologous prime-boost sequential immunizations using INO-4800 and CoronaVac®, an inactivated COVID-19 vaccine developed by Sinovac and validated by the World Health Organization (WHO) for emergency use. China'sCenter for Drug Evaluation of the National Medical Products Administration has allowed the initiation of two Advaccine-sponsored open-label, positive-control trials to evaluate the safety, tolerability, and immunogenicity of mixed boosted regimens. Both studies, which will be conducted in China, are anticipated to begin this fall and will involve healthy adult subjects 18 years of age or older. The companies completed cross prime-boost pre-clinical animal tests using INO-4800 and CoronaVac®, demonstrating that the prime-boost strategy can stimulate high-level of antigen specific binding antibodies, neutralizing antibodies by both live-virus neutralization assay and hACE2 receptor blocking assay, and antigen-specific T cell immune responses. In parallel with INO-4800, INOVIO is also developing a novel, pan-COVID, second-generation vaccine candidate, INO-4802, which is designed to protect against current and future variants of concern. In May 2021, INOVIO published a manuscript in BioRxiv that demonstrated cross-reactive immune responses against current and emerging viral variants using INO-4802 as either a first-line vaccine or potentially as a booster for individuals previously immunized with various wildtype strain-matched vaccines. Specifically, INO-4802 induced potent neutralizing antibodies and T cell responses against the original wildtype strain as well as against alpha, beta, gamma, and delta variants in pre-clinical models. INO-4800 is INOVIO's DNA vaccine candidate against SARS-CoV-2, the novel coronavirus that causes COVID-19. INOVIO has extensive experience working with coronaviruses. The company recently dosed its first participant in a Phase 2 trial for INO-4700, its DNA vaccine candidate for the prevention of Middle East Respiratory Syndrome (MERS), a coronavirus that is 100 times deadlier than COVID-19.Composed of a precisely designed DNA plasmid, INO-4800 is injected intradermally followed by electroporation using a proprietary smart device delivering the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune response. INO-4800 is the only nucleic-acid based vaccine that is stable at room temperature for more than a year, at 37o C for more than a month, has a five-year projected shelf life at normal refrigeration temperature and does not need to be frozen during transport or storage – all of which Inovio believes are important considerations for mass immunizations. INOVIO has 15 DNA medicine clinical programs currently in development and focused on HPV-associated diseases, cancer, and infectious diseases, including programs for Middle East Respiratory Syndrome, Lassa Fever and COVID-19 being developed under grants from the Coalition for Epidemic Preparedness Innovations and the U.S. Department of Defense. DNA medicines are composed of precisely designed DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer-sequencing technology and designed to produce a specific immune response in the body. INOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's proprietary hand-held smart device called CELLECTRA®. The CELLECTRA® device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T cell and antibody mediated immune responses. Administration with the CELLECTRA® device ensures that the DNA medicine is efficiently delivered directly into the body's cells, where it can go to work to drive an immune response. INOVIO's DNA medicines do not interfere with or change in any way an individual's own DNA. The advantages of INOVIO's DNA medicine platform are the relative speed at which DNA medicines can be designed and manufactured; the stability of the products, which do not require freezing in storage and transport; and the robust immune response, and tolerability that have been observed in clinical trials.With more than 3,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates with the potential to meet urgent global health needs.

Positive

INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine against Middle East Respiratory Syndrome, a Coronavirus Disease

2021-08-04 12:00:00

INOVIO announced that the company has dosed the first Phase 2 trial subject in its quest to develop the first vaccine against the Middle East Respiratory Syndrome (MERS). INOVIO's Phase 2 trial is designed to evaluate INO-4700, its DNA vaccine candidate for the prevention of MERS, a disease in the coronavirus family for which there are no approved vaccines. The multi-center Phase 2 trial is a randomized, double-blinded, placebo-controlled study designed to evaluate the safety, tolerability, and immunogenicity of INO-4700 administered with INOVIO's smart device, the CELLECTRA® 2000, in approximately 500 healthy adult volunteers. The study, which is sponsored by INOVIO and fully funded by the Coalition for Epidemic Preparedness Innovations (CEPI), is being conducted at sites in Jordan and Lebanon where MERS cases have been reported. This trial builds on the positive results of the Phase 1 trial, which were published in a peer-reviewed article in The Lancet Infectious Diseases entitled, "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, dose-escalation trial." Results from this first-in-human Phase 1 trial found high levels of binding antibodies in 92% (57 of 62) of evaluated subjects. Significant antigen-specific cytotoxic T-lymphocyte (CTL) responses were also observed. Importantly, 98% (61 of 62) of vaccinated subjects generated an antibody and/or T cell response against the MERS vaccine. INOVIO's pursuit of a MERS vaccine is funded by a previously announced $56 million grant from CEPI under which INOVIO is advancing two vaccine candidates through Phase 2 field trials against MERS and Lassa fever, respectively. INOVIO and CEPI plan to make a stockpile of these vaccines available for emergency use as soon as possible following Phase 2 testing. Despite the continuing threat of MERS outbreaks, there are no licensed vaccines or treatments for MERS. Since the virus was first identified in Saudi Arabia in 2012, the World Health Organization has reported more than 2,500 people with MERS disease globally and approximately 34% of those patients died. Twenty-seven countries have reported cases, including Korea where an outbreak in the summer of 2015 resulted in 186 cases with 20% dying. In contrast, the case-fatality ratio for COVID-19 before population vaccination was approximately 0.3% to 0.5%; while the case-fatality ratio for the 2003 SARS epidemic was 10%. MERS causes a rapidly progressive respiratory illness that may require intensive care treatment and mechanical ventilation in many patients.

Neutral

Inovio Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 09, 2021

2021-07-26 12:00:00

Inovio Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 09, 2021

Neutral

Inovio Pharmaceuticals, Inc. to Report Q2, 2021 Results on Aug 09, 2021

2021-07-26 12:00:00

Inovio Pharmaceuticals, Inc. announced that they will report Q2, 2021 results After-Market on Aug 09, 2021

Neutral

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021

2021-07-22 01:45:00

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021. Venue: Loews Coronado Bay Resort, San Diego, California, United States.

Neutral

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021

2021-07-21 14:31:00

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.

Neutral

Inovio Pharmaceuticals, Inc. Presents at Disease Prevention and Control Summit America 2021, Jul-20-2021 01:50 PM

2021-07-19 13:07:00

Inovio Pharmaceuticals, Inc. Presents at Disease Prevention and Control Summit America 2021, Jul-20-2021 01:50 PM. Venue: New York, New York, United States. Speakers: Kate E. Broderick, Senior Vice President of Research & Development.

Neutral

Terrapinn Holdings Ltd, NRx Pharmaceuticals, Inc., Disease Prevention and Control Summit America 2021, Jul 20, 2021 through Jul 21, 2021

2021-07-19 10:48:00

Terrapinn Holdings Ltd, NRx Pharmaceuticals, Inc., Disease Prevention and Control Summit America 2021, Jul 20, 2021 through Jul 21, 2021. Venue: New York, New York, United States.

Fundamental Summary

Inovio Pharmaceuticals's Q1 results, which were published on 2022-05-10, were good but relatively unimpressive. Individually, while their growth and income factors look healthy, the holistic financial picture it painted was less remarkable. Therefore, we gave Inovio Pharmaceuticals an overall score of 54 and a UNDERPERFORM recommendation.

Inovio Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 0.199074 million compared to USD 0.37112 million a year ago. Net loss was USD 79.07 million compared to USD 54.4 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.27 a year ago.

Business Description

Inovio Pharmaceuticals, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Sector Overview

Inovio Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Inovio Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 445.5 -10.2% 66
Liabilities 90.4 -6.1% 56
Price to Book 1.0 -62.4% 40
Cash & Equivalents 59.0 -17.1% 54
Equity 355.1 -11.2% 38
EBITDA -313.2 -6.4% 57
Total Revenues 1.6 -9.7% 96
Parameter Value Change Score
Return on Equity -70.1 0.6% 68
Net Cashflow -24.6 86.3% 67
Capital Expenditure -1.0 17.1% 92
Asset Turnover 0.0 -15.0% 44
Free Cashflow -1.1 -2.0% 67

* All values are TTM

The below chart reflects Inovio Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Inovio Pharmaceuticals's peer average final assessment score stands on 61.0, Inovio Pharmaceuticals's score is 54.

  •  INO
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 26 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 28 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 30 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 31 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 32 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 33 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 36 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 37 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 38 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 39 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 40 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Inovio Pharmaceuticals's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Inovio Pharmaceuticals's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 37.

Bearish 37
Close Price 1.82
52W Low 1.44
52W High 9.69
5D MA 1.92
50D MA 2.14
200D MA 4.55
MACD -0.07
RSI 6.89
STOCH 66.67

Balance Sheet Analysis

Several numbers from Inovio Pharmaceuticals's current balance sheet were concerning, in two areas in particular: Equity and Book Value Factors. Inovio Pharmaceuticals published concerning equity metrics for this filing. In the current report, equity stood at 355.1, which represents a -11.2% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. This performance is significantly less impressive than its peers and competitors. Therefore, their equity movement component earned a score of 38. Also, Inovio Pharmaceuticals's price to book ratio (P/B) was reported as 1.0 and represents -62.4% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. The company's book value factors were lackluster and showed that management hasn't figured out how to overperform expectations. Therefore, their book value factors earned a score of 40. At the same time, one balance sheet metric, Assets, was actually strongly positive. Inovio Pharmaceuticals assets on their balance sheet, moved to 445.5, which is a -10.2% change from the last period. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. The company's asset component, therefore, received a grade of 66. The company's balance sheet, Therefore, earned a score of 46.

Parameter Value Change Score
Assets 445.5 -10.2% 66
Liabilities 90.4 -6.1% 56
Price to Book 1.0 -62.4% 40
Cash & Equivalents 59.0 -17.1% 54
Equity 355.1 -11.2% 38
* All values are TTM

The below chart describes Inovio Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Inovio Pharmaceuticals received a balance sheet score of 46, the average of its peers stands on 62.0.

  •  INO
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 26 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 28 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 30 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 31 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 32 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 33 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 34 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 36 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 37 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 38 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 39 1
Geron Corporation 566.2M 69 72 37 59 62 60 40 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Overall, Inovio Pharmaceuticals's critical income statement metrics appear to signal strong support and a high likelihood of positive growth going forward. Inovio Pharmaceuticals reported highly encouraging numbers for its revenue efficiency. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their revenue efficiency, specifically in contrast to their industry peers', should support a positive movement in the company's stock price. The company's revenue efficiency, therefore, received a grade of 96. Also, In this filing, Inovio Pharmaceuticals reported a return on equity (ROE) ratio of -70.1, which represents a change of 0.6%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 68. However, one discouraging result, EBITDA, stood out. Inovio Pharmaceuticals's EBIDTA now sits at -313.2 and represents -6.4% change from the last reporting period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. Their EBITDA metrics are even more problematic when compared to their peers. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their EBITDA a grade of 57. Consequently, their income statement earned a rank of 72.

Parameter Value Change Score
EBITDA -313.2 -6.4% 57
Total Revenues 1.6 -9.7% 96
Return on Equity -70.1 0.6% 68
* All values are TTM

The below chart describes Inovio Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Inovio Pharmaceuticals received a income statement score of 72 , the average of its peers stands on 64.0.

  •  INO
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 26 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 28 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 29 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 30 1
IVERIC bio, Inc. 1.1B 84 58 79 70 31 1
FibroGen, Inc. 1.0B 48 74 63 67 32 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 33 1
ImmunoGen, Inc. 946.1M 40 73 71 64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 36 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 37 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 38 1
AnaptysBio, Inc. 586.3M 97 50 77 68 39 1
Geron Corporation 566.2M 89 67 73 78 40 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Inovio Pharmaceuticals appears likely to maintain its strong cash flow metrics and momentum going forward. Inovio Pharmaceuticals's management was effective in improving its CapEx, which now sits at -1.0 and represents 17.1% change from the previous report. The company appears to be headed in the right direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their CapEx movement received a grade of 92. Also, Inovio Pharmaceuticals's management was effective in improving their net cash flow, which now sits at -24.6 and represents a 86.3% change from the previous report. This industry-leading net cash flow momentum should reinforce broader positive momentum for its's stock price going forward. Consequently, their net cash flow movement received a grade of 67. On the other hand, Asset Turnover, jumped out as looking problematic. Asset turnover metrics during this period were surprisingly weak. Their reported asset turnover metrics of 0.0, which represents a -15.0% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. The company's asset turnover metrics seem especially problematic relative to their peers. Underwhelming results in asset turnover metrics often lead to negative pressure in stock prices, so we rated its asset turnover momentum 44. The company's cash flow received an overall score of 71.

Parameter Value Change Score
Net Cashflow -24.6 86.3% 67
Capital Expenditure -1.0 17.1% 92
Asset Turnover 0.0 -15.0% 44
Free Cashflow -1.1 -2.0% 67
* All values are TTM

The below chart describes Inovio Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Inovio Pharmaceuticals received a cash flow score of 71, the average of its peers stands on 67.0.

  •  INO
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 26 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 28 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 29 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 30 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 31 1
FibroGen, Inc. 1.0B 86 74 48 87 84 32 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 33 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 34 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 36 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 37 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 38 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 39 1
Geron Corporation 566.2M 78 68 49 81 77 40 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.